Skip to main content
SpringerLink
Log in

Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Subclinical hypercortisolism (SH) is a newly characterized hormonal disorder that is almost exclusively detected in the context of incidentally discovered adrenal masses. The diagnostic criteria used for the definition of this condition are at present controversial. Amongst the various tests used for the detection of this abnormality (dexamethasone suppression, urinary free cortisol, ACTH levels, midnight serum or salivary cortisol concentrations, ACTH responses to CRH stimulation), the dexamethasone suppression tests (DST) seem to better accomplish the task of unmasking subtle abnormalities of cortisol secretion. Several versions of DST have been used: the 1-mg overnight, the 3-mg overnight and the classical 2-day low-dose DST. This latter test has the theoretical advantage that, by more efficiently suppressing pituitary ACTH secretion, it may provide a measure of the residual (ie non-ACTH-dependent) cortisol secretion from the adrenal mass. In this way, post-dexamethasone cortisol concentrations may quantify the degree of autonomous cortisol hypersecretion. In fact, post-dexamethasone cortisol concentrations have a negative correlation with basal ACTH levels and a positive correlation with midnight cortisol concentrations as well as the size of the incidentally discovered adrenal mass. Most of the existing data indicate that SH detected in the context of adrenal incidentalomas may have some clinically significant implications. In fact, patients with higher post-dexamethasone cortisol concentrations demonstrate higher lipid levels and lower bone mass densities. It has also been suggested that SH may be responsible for biochemical and phenotypic changes reminiscent of the metabolic syndrome. In summary, SH does exist and is associated with a negative impact in patients’ health; however, hormonal cut-off criteria for decision-making remain to be defined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beierwaltes WH, Sturman MF, Ryo U, Ice RD. Imaging functional nodules of adrenal glands with 131-I-9-iodocholesterol. J Nucl Med 1973, 15: 246–51.

    Google Scholar 

  2. Charbonnel B, Chatal JF, Ozanne P. Does the corticoadrenal adenoma with pre-Cushing’s syndrome exist? J Nucl Med 1981, 22: 1059–61.

    CAS  PubMed  Google Scholar 

  3. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med 2003, 138: 424–9.

    Article  PubMed  Google Scholar 

  4. Sakai K, Horiba N, Sakai Y, et al. A case of preclinical Cushing’s disease only accompanied by obesity and glucose intolerance. Folia Endocrinol Jpn 1994, 70: 726.

    Google Scholar 

  5. Takao T, Mimoto T, Yamamoto M, Hashimoto K. Preclinical Cushing disease. Arch Intern Med 2001, 161: 892–3.

    Article  CAS  PubMed  Google Scholar 

  6. Nagai T, Imamura M, Misumi S, Mori M. Subclinical Cushing’s disease accompanied by malignant hypertension and diabetes mellitus. Intern Med 2002, 41: 566–70.

    Article  PubMed  Google Scholar 

  7. Leibowitz G, Tsur A, Chayen SD, et al. Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrinol (Oxf) 1996, 44: 717–22.

    Article  CAS  Google Scholar 

  8. Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab 2003, 88: 5808–13.

    Article  CAS  PubMed  Google Scholar 

  9. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991, 72: 39–45.

    Article  CAS  PubMed  Google Scholar 

  10. Peacey S, Guo CY, Robinson A, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997, 46: 255–61.

    Article  CAS  Google Scholar 

  11. Reincke M, Nieke J, Krestin GP, et al. Preclinical Cushing’s syndrome in adrenal incidentalomas: comparison with adrenal Cushing’s syndrome. J Clin Endocrinol Metab 1992, 75: 826–32.

    CAS  PubMed  Google Scholar 

  12. Terzolo M, Ali A, Osella G, et al. Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) 1998, 48: 89–97.

    Article  CAS  Google Scholar 

  13. Tsagarakis S, Kokkoris P, Roboti C, et al. The low-dose dexamethasone suppression test in patients with adrenal incidentalomas: comparisons with clinically euadrenal subjects and patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 1998, 48: 627–33.

    Article  CAS  Google Scholar 

  14. Huiras CM, Pehling GB, Caplan RH. Adrenal insufficiency after operative removal of apparently nonfunctioning adrenal adenomas. JAMA 1989, 261: 894–8.

    Article  CAS  PubMed  Google Scholar 

  15. Kloos RT, Gross MD, Shapiro B. Investigation of incidentally discovered, biochemically non-hypersecretory benign adrenal adenomas: a review of the current knowledge and areas for future investigation. Intern Med 1994, 2: 9–15.

    Google Scholar 

  16. Osella G, Terzolo M, Borretta G, et al. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab 1994, 79: 1532–9.

    Article  CAS  PubMed  Google Scholar 

  17. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence of low dose dexamethasone suppression test to screen for Cushing’s syndrome-recommendation for a protocol for biochemistry laboratories. Ann Clin Biochem 1997, 34: 222–9.

    Article  CAS  PubMed  Google Scholar 

  18. Huizengua NA, Koper JW, de Lange P, et al. Interperson variability but intraperson stability of baseline serum cortisol concentrations and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 1998, 83: 47–54.

    Google Scholar 

  19. Valli N, Catargi B, Ronci N, et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol 2001, 144: 401–8.

    Article  CAS  PubMed  Google Scholar 

  20. Barzon L, Fallo F, Sonino N, Boscaro M. Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas. Eur J Endocrinol 2001, 145: 223–4.

    Article  CAS  PubMed  Google Scholar 

  21. Trainer PJ, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxf) 1991,34: 317–30.

    Article  CAS  Google Scholar 

  22. Ambrosi B, Peverelli S, Passini E, et al. Abnormalities of endocrine function in patients with clinically silent adrenal masses. Eur J Endocrinol 1995, 132: 422–8.

    Article  CAS  PubMed  Google Scholar 

  23. Tsagarakis S, Roboti C, Kokkoris P, Vassiliou V, Alevizaki C, Thalassinos N. Elevated postdexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxf) 1998, 49: 165–71.

    Article  CAS  Google Scholar 

  24. Lavoie H, Lacroix A. Partially autonomous cortisol secretion by incidentally discovered adrenal adenomas. Trends Endocrinol Metab 1995, 6: 191–7.

    Article  CAS  PubMed  Google Scholar 

  25. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000, 85: 1440–8.

    CAS  PubMed  Google Scholar 

  26. Hadjidakis D, Tsagarakis S, Roboti C, et al. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol (Oxf) 2003, 58: 72–7.

    Article  CAS  Google Scholar 

  27. Chidiac RM, Aron DC. Incidentalomas: A disease of modern technology. Endocrinol Metab Clin North Am 1997, 26: 233–53.

    Article  CAS  PubMed  Google Scholar 

  28. Morioka M, Fujii T, Matsuki T, et al. Preclinical Cushing’s syndrome: report on seven cases and review of the literature. Int J Urol 2000, 7: 126–32.

    Article  CAS  PubMed  Google Scholar 

  29. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 2001, 54: 797–804.

    Article  CAS  Google Scholar 

  30. Crapo L. Cushing’s syndrome: a review of diagnostic tests. Metabolism 1979, 28: 955–77.

    Article  CAS  PubMed  Google Scholar 

  31. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999, 84: 440–8.

    CAS  PubMed  Google Scholar 

  32. Aron DC. Adrenal incidentalomas and glucocorticoid autonomy. Clin Endocrinol (Oxf) 1998, 49: 157–8.

    Article  CAS  Google Scholar 

  33. Putignano P, Bertolini M, Losa M, Cavagnini F. Screening for Cushing’s syndrome in obese women with and without polycystic ovary syndrome. J Endocrinol Invest 2003, 26: 539–44.

    CAS  PubMed  Google Scholar 

  34. Terzolo M, Osella G, Ali A, et al. Different patterns of steroid secretion in patients with adrenal incidentaloma. J Clin Endocrinol Metab 1996, 81: 740–4.

    CAS  PubMed  Google Scholar 

  35. McLeod M, Thompson N, Gross M, et al. Subclinical Cushing’s syndrome in patients with adrenal gland incidentalomas. Pitfalls in diagnosis and management. Am Surg 1990, 56: 398–403.

    CAS  Google Scholar 

  36. Terzolo M, Pia A, Ali A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 2002, 87: 998–1003.

    Article  CAS  PubMed  Google Scholar 

  37. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxf) 1995, 43: 545–50.

    Article  CAS  Google Scholar 

  38. Papanicolaou DA, Yanovski JA, Cutler GB, Chrousos GP, Nieman LK. A single midnight cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 1998, 83: 1163–7.

    CAS  PubMed  Google Scholar 

  39. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 2005, 34: 423–39.

    Article  PubMed  Google Scholar 

  40. Terzolo M, Bovio S, Pia A, et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol 2005, 153: 307–15.

    Article  CAS  PubMed  Google Scholar 

  41. Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 1997, 46: 29–37.

    Article  Google Scholar 

  42. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 2000, 85: 637–44.

    CAS  PubMed  Google Scholar 

  43. Tanabe A, Naruse M, Nishikawa T, et al. Autonomy of cortisol secretion in clinically silentadrenal incidentaloma. Horm Metab Res 2001, 33: 444–50.

    Article  CAS  PubMed  Google Scholar 

  44. Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000, 29: 42–56.

    Article  Google Scholar 

  45. Dominguez-Gadea L, Diez L, Piedrola-Maroto G, Crespo A. Scintigraphic diagnosis of subclinical Cushing’s syndrome in patients with adrenal incidentalomas. Nucl Med Commun 1996, 17: 29–32.

    Article  CAS  PubMed  Google Scholar 

  46. Gross MD, Wilton GP, Shapiro B, et al. Functional and scintigraphic evaluation of the silent adrenal mass. J Nucl Med 1987, 28: 1401–7.

    CAS  PubMed  Google Scholar 

  47. Bardet S, Rohmer V, Murat A, et al. 131I-b-Iodomethylnor-cholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas. Clin Endocrinol (Oxf) 1996, 44: 587–96.

    Article  CAS  Google Scholar 

  48. Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab 1998, 83: 55–62.

    CAS  PubMed  Google Scholar 

  49. Caplan RH, Strutt PJ, Wickus GG. Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg 1994, 129: 291–6.

    Article  CAS  PubMed  Google Scholar 

  50. Bondanelli M, Campo M, Trasforini G, et al. Evaluation of hormonal function in a series of incidentally discovered adrenal masses. Metabolism 1997, 46: 107–13.

    Article  CAS  PubMed  Google Scholar 

  51. Bulow B, Ahren B. Adrenal incidentaloma: experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med 2002, 252: 239–46.

    Article  CAS  PubMed  Google Scholar 

  52. Tutuncu NB, Gedik O. Adrenal incidentaloma: report of 33 cases. J Surg Oncol 1999, 70: 247–50.

    Article  CAS  PubMed  Google Scholar 

  53. Favia G, Lumachi F, Basso S, D’Amico D. Management of incidentally discovered adrenal masses and risk of malignancy. Surgery 2000, 128: 918–24.

    Article  CAS  PubMed  Google Scholar 

  54. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991, 110: 1014–21.

    CAS  PubMed  Google Scholar 

  55. Jockenhovel F, Kuck W, Hauffa B, et al. Conservative and surgical management of incidentally discovered adrenal tumors (incidentalomas). J Endocrinol Invest 1992, 15: 331–7.

    CAS  PubMed  Google Scholar 

  56. Barry MK, van Heerden JA, Farley DR, Grant CS, Thompson GB, Ilstrup DM. Can adrenal incidentalomas be safely observed? World J Surg 1998, 22: 599–603.

    Article  CAS  PubMed  Google Scholar 

  57. Grossrubatscher E, Vignati F, Possa M, Loli P. The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation. J Endocrinol Invest 2001, 24: 846–55.

    Article  CAS  PubMed  Google Scholar 

  58. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003, 149: 273–85.

    Article  CAS  PubMed  Google Scholar 

  59. Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002, 147: 489–94.

    Article  CAS  PubMed  Google Scholar 

  60. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 1999, 84: 520–6.

    CAS  PubMed  Google Scholar 

  61. Zelissen P, Croughs R, Van Rijk P, Raymakers J. Effect of glucocorticoid replacement on bone mineral density in patients with Addison disease. Ann Intern Med 1994, 120: 207–10.

    Article  CAS  PubMed  Google Scholar 

  62. Al-Shoumer K, Beshyah S, Niththyananthan R, Johnston D. Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol (Oxf) 1995, 42: 85–90.

    Article  CAS  Google Scholar 

  63. McConnell E, Bell P, Hadden D, McCance D, Sheridan B, Atkinson A. Prevalence of diabetes and impaired glucose tolerance in adult hypopituitarism on low dose oral hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 2001, 54: 593–9.

    Article  CAS  Google Scholar 

  64. Beshyah S, Henderson A, Niththyananthan R, Sharp P, Johnston DG. Metabolic abnormalities in growth hormone deficient adults. II. Carbohydrate tolerance and lipid metabolism. Endocrinol Metab 1994, 1: 173–80.

    Google Scholar 

  65. Monson J. The assessment of glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 1997, 46: 269–70.

    Article  CAS  Google Scholar 

  66. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 1999, 50: 1–15.

    Article  CAS  Google Scholar 

  67. Stewart P, Sheppard M. Mortality and hypopituitarism. Growth Horm IGF Res 1999, 9(Suppl A): 15–9.

    Article  PubMed  Google Scholar 

  68. Wei L, MacDonald T, Walker B. Use of glucocorticoid and risk of cardiovascular disease in a population-based cohort study of 164,133 participants. Endocrine 2003, 5: 9.

    Google Scholar 

  69. Torlontano M, Chiodini I, Pileri M, et al. Altered bone mass and turnover in female patients with adrenal incidentaloma: the effect of subclinical hypercortisolism. J Clin Endocrinol Metab 1999, 84: 2381–5.

    Article  CAS  PubMed  Google Scholar 

  70. Chiodini I, Torlontano M, Carnevale V, et al. Bone loss rate in adrenal incidentalomas: a longitudinal study. J Clin Endocrinol Metab 2001, 86: 5337–41.

    Article  CAS  PubMed  Google Scholar 

  71. Chiodini I, Tauchmanova L, Torlontano M, et al. Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J Clin Endocrinol Metab 2002, 87: 5491–4.

    Article  CAS  PubMed  Google Scholar 

  72. Bardet S, Rohmer V, Boux de Casson F. Densité minérale osseuse et marqueurs biologiques de remaniement osseux chez des patients porteurs d’incidentalome surrénalien: effet d’un hypercortisolisme infraclinique. Rev Med Interne 2002, 23: 508–17.

    Article  CAS  PubMed  Google Scholar 

  73. Osella G, Reimondo G, Peretti P, et al. The patients with incidentally discovered adrenal adenoma (incidentaloma) are not at increased risk of osteoporosis. J Clin Endocrinol Metab 2001, 86: 604–7.

    Article  CAS  PubMed  Google Scholar 

  74. Chiodini I, Guglielmi G, Battista C, et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004, 89: 2237–41.

    Article  CAS  PubMed  Google Scholar 

  75. Sartorio A, Conti A, Ferrero S, et al. Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing’s syndrome and in patients with adrenal incidentaloma. Eur J Endocrinol 1998, 138: 146–52.

    Article  CAS  PubMed  Google Scholar 

  76. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002, 87: 4872–8.

    Article  PubMed  Google Scholar 

  77. Fernandez-Real JM, Ricart EW, Simo R, et al. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Clin Endocrinol (Oxf) 1998, 49: 53–61.

    Article  CAS  Google Scholar 

  78. Garrapa G, Pantanetti P, Arnaldi G, et al. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clin Endocrinol Metab 2001, 86: 5301–6.

    CAS  PubMed  Google Scholar 

  79. Bernini G, Moretti A, Iacconi P, et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur J Endocrinol 2003, 148: 213–9.

    Article  CAS  PubMed  Google Scholar 

  80. Terzolo M, Bossoni S, Ali A, et al. Growth hormone responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J Clin Endocrinol Metab 2000, 85: 1310–5.

    Article  CAS  PubMed  Google Scholar 

  81. Tzanela M, Zianni D, Stylianidou C, Karavitaki N, Tsagarakis S, Thalassinos N. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion. Clin Endocrinol (Oxf) 2005, 62: 597–602.

    Article  CAS  Google Scholar 

  82. Emral R, Uysal AR, Asik M, et al. Prevalence of subclinical Cushing’s syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 2003, 50: 399–408.

    Article  PubMed  Google Scholar 

  83. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 2002, 146: 61–6.

    Article  CAS  PubMed  Google Scholar 

  84. Tjan-Heijnen V, Hermus A, Kemink S, et al. Preclinical Cushing’s syndrome in patients with an adrenal incidentaloma. NethJ Med 1998, 52: 111–5.

    Article  CAS  Google Scholar 

  85. Gratsias Y, Moutsatsou P, Chrysanthopoulou G, Tsagarakis S, Thalassinos N, Sekeris CE. Diurnal changes in glucocorticoid sensitivity in human peripheral blood samples. Steroids 2000, 65: 851–6.

    Article  CAS  PubMed  Google Scholar 

  86. Vassiliadi D, Gratsias Y, Tsagarakis S, et al. Glucocorticoid sensitivity assessed in peripheral blood cells does not correlate with the feedback sensitivity of the hypothalamo-pituitary adrenal axis. Hormones 2002, 1: 233–8.

    Article  Google Scholar 

  87. Ebrecht M, Buske-Kirschbaum A, Hellhammer D, et al. Tissue specificity of glucocorticoid sensitivity in healthy adults. J Clin Endocrinol Metab 2000, 85: 3733–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Athens’ Polyclinic 105, 52, Athens, Greece

    S. Tsagarakis MD, PhD

  2. Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, Greece

    D. Vassiliadi & N. Thalassinos

Authors
  1. S. Tsagarakis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Vassiliadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Thalassinos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Tsagarakis MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tsagarakis, S., Vassiliadi, D. & Thalassinos, N. Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications. J Endocrinol Invest 29, 471–482 (2006). https://doi.org/10.1007/BF03344133

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344133

Key-words

Search

Navigation